[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"generalized-lipodystrophy-gld\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:generalized-lipodystrophy-gld":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":4,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":15,"phases":4,"briefSummary":16,"conditions":17,"keywords":21,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":30,"locationsCount":4},"100417005",false,"NCT04710056","Expanded Access to REGN4461 for Patients With Diseases Associated With Deficient Leptin Signaling","Key Inclusion: N\u002FA\n\nKey Exclusion: N\u002FA","ALL","EXPANDED_ACCESS","Provide Expanded Access to REGN4461 for patients with diseases associated with deficient leptin signaling.",[18,19,20],"Lipodystrophy","Generalized Lipodystrophy (GLD)","Monogenic Obesity (MOB)",[22,23,24],"Leptin (LEP)","Leptin Receptors (LEPR)","Biallelic Loss of Function Variants of the LEP Gene","AVAILABLE","2026-03-10",{"date":28,"type":29},"2026-03-12","ACTUAL",{"name":31,"class":32},"Regeneron Pharmaceuticals","INDUSTRY",""]